Author: MclinPharm, Syed Imran Ahmed; Khan, Shahzad
Title: Coagulopathy and Plausible Benefits of Anticoagulation Among COVID-19 Patients Cord-id: diwqblnl Document date: 2020_6_27
ID: diwqblnl
Snippet: The exceptional outbreak of COVID-19 pandemic has let the scientific community to work closely and quickly learnt things in a very short period of time. This has let us recognise that thromboembolic complications are responsible morbidity and mortality among the COVID-19 infected patients. Available data have suggested a possible multifactorial basis of this complications, and while efforts are being made to treat this infection, preventive measure with the use of systemic anticoagulation were q
Document: The exceptional outbreak of COVID-19 pandemic has let the scientific community to work closely and quickly learnt things in a very short period of time. This has let us recognise that thromboembolic complications are responsible morbidity and mortality among the COVID-19 infected patients. Available data have suggested a possible multifactorial basis of this complications, and while efforts are being made to treat this infection, preventive measure with the use of systemic anticoagulation were quickly adopted to deal with this complication. Despite obvious benefits as appeared with the use of systemic anticoagulation, most of the emerged data were retrospective, and hence raise questions on the possible interplay of the confounders as well as long term benefits and safety of systemic anticoagulation.
Search related documents:
Co phrase search for related documents- acute ards respiratory distress syndrome and adjuvant therapy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- acute ards respiratory distress syndrome and lmwh receive: 1
- acute ards respiratory distress syndrome and long term benefit: 1
- acute ards respiratory distress syndrome and low molecular: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- acute ards respiratory distress syndrome and low molecular weight: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- acute ards respiratory distress syndrome and low molecular weight heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- acute ards respiratory distress syndrome and lung microthrombi: 1
- adhesion molecule and adjuvant therapy: 1, 2
- adjuvant therapy and low molecular: 1, 2, 3, 4
- adjuvant therapy and low molecular weight: 1, 2, 3, 4
- adjuvant therapy and low molecular weight heparin: 1, 2, 3, 4
- lmwh receive and low molecular: 1, 2
- lmwh receive and low molecular weight: 1, 2
- lmwh receive and low molecular weight heparin: 1, 2
- low molecular and lwmh weight heparin: 1
- low molecular lwmh weight heparin and lwmh weight heparin: 1
- low molecular weight and lwmh weight heparin: 1
- low molecular weight heparin and lwmh weight heparin: 1
- low molecular weight heparin lwmh and lwmh weight heparin: 1
Co phrase search for related documents, hyperlinks ordered by date